<p>Adage Capital Partners GP L.L.C. 在最近向美國證券交易委員會提交的 13F 表格中表示，在第一季度將其在史賽克公司（NYSE:SYK - 免費報告）的持股減少了 7.0%。該公司在季度內出售了 10,044 股後，持有 134,347 股這家醫療科技公司的股票。Adage Capital Partners GP L.L.C. 在史賽克的持股在最近一個季度末價值為 50,011,000 美元。</p>
<ul>
<li>如果你只能持有 3 項投資一輩子，請考慮這些</li>
</ul>
<p>其他幾家機構投資者最近也對其在 SYK 的持倉進行了調整。Elefante Mark B 在第四季度購買了約 337,000 美元的新股份。Mogy Joel R Investment Counsel Inc. 在第一季度將其在史賽克的持股增加了 3.4%。Mogy Joel R Investment Counsel Inc. 現在持有 98,216 股這家醫療科技公司的股票，價值 36,561,000 美元，此前在上個季度又購買了 3,218 股。Ferguson Wellman Capital Management Inc. 在第一季度將其在史賽克的持股增加了 1.9%。Ferguson Wellman Capital Management Inc. 現在持有 174,871 股這家醫療科技公司的股票，價值 65,096,000 美元，此前在上個季度又購買了 3,341 股。Harbor Capital Advisors Inc. 在第一季度購買了約 1,840,000 美元的新股份。最後，Mar Vista Investment Partners LLC 在第一季度將其在史賽克的持股增加了 10.2%。Mar Vista Investment Partners LLC 現在持有 90,187 股這家醫療科技公司的股票，價值 33,572,000 美元，此前在上個季度又購買了 8,353 股。機構投資者目前持有該公司 77.09% 的股票。</p>
<h2>內部買賣</h2>
<p>在其他史賽克的新聞中，董事 Ronda E. Stryker 於 8 月 6 日星期三出售了 200,000 股公司的股票。該股票以平均價格 376.45 美元出售，總交易額為 75,290,000.00 美元。交易後，該董事在公司持有 3,222,108 股，估值約為 1,212,962,556.60 美元。這代表其持股減少了 5.84%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Viju Menon 於 8 月 25 日星期一出售了 500 股公司的股票。該股票以平均價格 390.61 美元出售，總價值為 195,305.00 美元。交易後，該內部人士在公司持有 12,511 股，估值為 4,886,921.71 美元。這筆交易代表其持股減少了 3.84%。該銷售的披露信息可以在這裏找到。當前 5.20% 的股票由公司內部人士持有。</p>
<h2>史賽克股票表現</h2>
<ul>
<li>3 只股票助力人工智能進入醫療保健領域</li>
</ul>
<p>史賽克股票在星期四開盤價為 388.14 美元。該公司的流動比率為 1.78，速動比率為 1.06，債務與股本比率為 0.70。該公司的 50 日移動平均線為 389.48 美元，200 日移動平均線為 379.51 美元。該公司的市值為 1483.9 億美元，市盈率為 51.41，市盈增長比率為 2.85，貝塔值為 0.93。史賽克公司的 1 年最低價為 329.16 美元，1 年最高價為 406.19 美元。</p>
<p>史賽克（NYSE:SYK - 獲取免費報告）最近一次發佈財報是在 7 月 31 日星期四。這家醫療科技公司報告本季度每股收益為 3.13 美元，超出分析師一致預期的 3.07 美元，超出幅度為 0.06 美元。史賽克的淨利潤率為 12.25%，股本回報率為 23.94%。該公司本季度的收入為 60.2 億美元，而分析師預期為 59.2 億美元。在去年同期，該公司每股收益為 2.81 美元。史賽克本季度的收入同比增長 11.1%。史賽克已將其 2025 財年的每股收益指導設定為 13.400-13.600。賣方分析師預計史賽克公司本年度將發佈 13.47 的每股收益。</p>
<h2>史賽克宣佈分紅</h2>
<ul>
<li>波士頓科學：為什麼這家醫療科技巨頭不會放慢腳步</li>
</ul>
<p>該公司最近還宣佈了一項季度分紅，將於 10 月 31 日星期五支付。9 月 30 日星期二的股東將獲得每股 0.84 美元的分紅。除息日為 9 月 30 日星期二。這代表年化分紅為 3.36 美元，分紅收益率為 0.9%。史賽克的分紅支付比率為 44.50%。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商已對 SYK 發佈了報告。華爾街 Zen 在 7 月 18 日星期五的研究報告中將史賽克的評級從 “持有” 上調至 “買入”。Needham &amp; Company LLC 在 8 月 1 日的研究報告中將史賽克的目標價從 442.00 美元上調至 448.00 美元，並給予該公司 “買入” 評級。BTIG Research 在 7 月 14 日星期一的研究報告中重申了對史賽克股票的 “買入” 評級。花旗集團在 5 月 22 日星期四的研究報告中重申了 “買入” 評級，並將史賽克股票的目標價設定為 455.00 美元（上調自 443.00 美元）。最後，Evercore ISI 在 7 月 8 日星期二的研究報告中將史賽克的目標價從 390.00 美元上調至 415.00 美元，並給予該公司 “跑贏大盤” 評級。十五位研究分析師對該股票給予了 “買入” 評級，四位給予了 “持有” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 430.10 美元。</p>
<p><strong>閲讀我們最新的 SYK 股票報告</strong></p>
<h2>史賽克公司簡介</h2>
<p>（免費報告）</p>
<p>史賽克公司是一家醫療科技公司。該公司通過兩個部門運營，分別是醫療外科和神經技術，以及骨科和脊柱。骨科和脊柱部門提供用於全關節置換的植入物，如髖關節、膝關節和肩關節，以及創傷和四肢手術。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比史賽克更好</li>
<li>今日最大股票虧損者 - 今日最大百分比下跌者</li>
<li>開學購物達到 400 億美元：現在值得關注的三隻零售股票</li>
<li>什麼是盈利驚喜？</li>
<li>谷歌母公司股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
<li>如何計算期權利潤</li>
<li>為什麼高通在經歷幾個月的滯後後表現優於英偉達</li>
</ul>
<p><strong>想看看其他對 SYK 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取史賽克公司（NYSE:SYK - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在史賽克嗎？</h2>
<p>在考慮史賽克之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而史賽克並不在名單上。</p>
<p>雖然史賽克目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

史賽克

<p>Adage Capital Partners GP L.L.C. 在第一季度減少了對史賽克（NYSE:SYK）的持股比例，減持了 7.0%，出售了 10,044 股，剩餘持有 134,347 股，市值為 5000 萬美元。其他機構投資者也調整了他們的持倉。史賽克的股票開盤價為 388.14 美元，市值為 1483.9 億美元。該公司報告第二季度每股收益為 3.13 美元，超出預期，並宣佈每股季度分紅為 0.84 美元，將於 10 月 31 日支付</p>

<p>Adage Capital Partners GP L.L.C. lowered its position in Stryker Corporation (NYSE:SYK - Free Report) by 7.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 134,347 shares of the medical technology company's stock after selling 10,044 shares during the quarter. Adage Capital Partners GP L.L.C.'s holdings in Stryker were worth $50,011,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Adage Capital Partners GP L.L.C. 在最近向美國證券交易委員會提交的 13F 表格中表示，在第一季度將其在史賽克公司（NYSE:SYK - 免費報告）的持股減少了 7.0%。該公司在季度內出售了 10,044 股後，持有 134,347 股這家醫療科技公司的股票。Adage Capital Partners GP L.L.C. 在史賽克的持股在最近一個季度末價值為 50,011,000 美元。</p>
</div><ul>
<li>If You Could Only Hold 3 Investments for Life, Consider These</li>
</ul>
<div class="lb-trans"><ul>
<li>如果你只能持有 3 項投資一輩子，請考慮這些</li>
</ul>
</div><p>Several other institutional investors have also recently made changes to their positions in SYK. Elefante Mark B bought a new stake in Stryker during the fourth quarter worth about $337,000. Mogy Joel R Investment Counsel Inc. lifted its stake in Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company's stock worth $36,561,000 after purchasing an additional 3,218 shares during the last quarter. Ferguson Wellman Capital Management Inc. lifted its stake in Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company's stock worth $65,096,000 after purchasing an additional 3,341 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in Stryker during the first quarter worth about $1,840,000. Finally, Mar Vista Investment Partners LLC lifted its stake in Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company's stock worth $33,572,000 after purchasing an additional 8,353 shares during the last quarter. Institutional investors own 77.09% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也對其在 SYK 的持倉進行了調整。Elefante Mark B 在第四季度購買了約 337,000 美元的新股份。Mogy Joel R Investment Counsel Inc. 在第一季度將其在史賽克的持股增加了 3.4%。Mogy Joel R Investment Counsel Inc. 現在持有 98,216 股這家醫療科技公司的股票，價值 36,561,000 美元，此前在上個季度又購買了 3,218 股。Ferguson Wellman Capital Management Inc. 在第一季度將其在史賽克的持股增加了 1.9%。Ferguson Wellman Capital Management Inc. 現在持有 174,871 股這家醫療科技公司的股票，價值 65,096,000 美元，此前在上個季度又購買了 3,341 股。Harbor Capital Advisors Inc. 在第一季度購買了約 1,840,000 美元的新股份。最後，Mar Vista Investment Partners LLC 在第一季度將其在史賽克的持股增加了 10.2%。Mar Vista Investment Partners LLC 現在持有 90,187 股這家醫療科技公司的股票，價值 33,572,000 美元，此前在上個季度又購買了 8,353 股。機構投資者目前持有該公司 77.09% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部買賣</h2>
</div><p>In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他史賽克的新聞中，董事 Ronda E. Stryker 於 8 月 6 日星期三出售了 200,000 股公司的股票。該股票以平均價格 376.45 美元出售，總交易額為 75,290,000.00 美元。交易後，該董事在公司持有 3,222,108 股，估值約為 1,212,962,556.60 美元。這代表其持股減少了 5.84%。該交易已在向證券交易委員會的法律文件中披露，相關信息可通過 SEC 網站獲取。此外，內部人士 Viju Menon 於 8 月 25 日星期一出售了 500 股公司的股票。該股票以平均價格 390.61 美元出售，總價值為 195,305.00 美元。交易後，該內部人士在公司持有 12,511 股，估值為 4,886,921.71 美元。這筆交易代表其持股減少了 3.84%。該銷售的披露信息可以在這裏找到。當前 5.20% 的股票由公司內部人士持有。</p>
</div><h2>Stryker Stock Performance</h2>
<div class="lb-trans"><h2>史賽克股票表現</h2>
</div><ul>
<li>3 Stocks Helping to Bring AI to Healthcare</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只股票助力人工智能進入醫療保健領域</li>
</ul>
</div><p>Stryker stock opened at $388.14 on Thursday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average of $389.48 and a 200-day moving average of $379.51. The firm has a market cap of $148.39 billion, a P/E ratio of 51.41, a P/E/G ratio of 2.85 and a beta of 0.93. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19.</p>
<div class="lb-trans"><p>史賽克股票在星期四開盤價為 388.14 美元。該公司的流動比率為 1.78，速動比率為 1.06，債務與股本比率為 0.70。該公司的 50 日移動平均線為 389.48 美元，200 日移動平均線為 379.51 美元。該公司的市值為 1483.9 億美元，市盈率為 51.41，市盈增長比率為 2.85，貝塔值為 0.93。史賽克公司的 1 年最低價為 329.16 美元，1 年最高價為 406.19 美元。</p>
</div><p>Stryker (NYSE:SYK - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the prior year, the business posted $2.81 earnings per share. Stryker's revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Sell-side analysts expect that Stryker Corporation will post 13.47 EPS for the current year.</p>
<div class="lb-trans"><p>史賽克（NYSE:SYK - 獲取免費報告）最近一次發佈財報是在 7 月 31 日星期四。這家醫療科技公司報告本季度每股收益為 3.13 美元，超出分析師一致預期的 3.07 美元，超出幅度為 0.06 美元。史賽克的淨利潤率為 12.25%，股本回報率為 23.94%。該公司本季度的收入為 60.2 億美元，而分析師預期為 59.2 億美元。在去年同期，該公司每股收益為 2.81 美元。史賽克本季度的收入同比增長 11.1%。史賽克已將其 2025 財年的每股收益指導設定為 13.400-13.600。賣方分析師預計史賽克公司本年度將發佈 13.47 的每股收益。</p>
</div><h2>Stryker Announces Dividend</h2>
<div class="lb-trans"><h2>史賽克宣佈分紅</h2>
</div><ul>
<li>Boston Scientific: Why This MedTech Giant Isn’t Slowing Down</li>
</ul>
<div class="lb-trans"><ul>
<li>波士頓科學：為什麼這家醫療科技巨頭不會放慢腳步</li>
</ul>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker's dividend payout ratio is 44.50%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 10 月 31 日星期五支付。9 月 30 日星期二的股東將獲得每股 0.84 美元的分紅。除息日為 9 月 30 日星期二。這代表年化分紅為 3.36 美元，分紅收益率為 0.9%。史賽克的分紅支付比率為 44.50%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages have issued reports on SYK. Wall Street Zen raised Stryker from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Friday, July 18th. Needham &amp; Company LLC raised their price objective on Stryker from $442.00 to $448.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, August 1st. BTIG Research reaffirmed a &#34;buy&#34; rating on shares of Stryker in a research note on Monday, July 14th. Citigroup reaffirmed a &#34;buy&#34; rating and set a $455.00 price objective (up from $443.00) on shares of Stryker in a research note on Thursday, May 22nd. Finally, Evercore ISI raised their price objective on Stryker from $390.00 to $415.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $430.10.</p>
<div class="lb-trans"><p>幾家券商已對 SYK 發佈了報告。華爾街 Zen 在 7 月 18 日星期五的研究報告中將史賽克的評級從 “持有” 上調至 “買入”。Needham &amp; Company LLC 在 8 月 1 日的研究報告中將史賽克的目標價從 442.00 美元上調至 448.00 美元，並給予該公司 “買入” 評級。BTIG Research 在 7 月 14 日星期一的研究報告中重申了對史賽克股票的 “買入” 評級。花旗集團在 5 月 22 日星期四的研究報告中重申了 “買入” 評級，並將史賽克股票的目標價設定為 455.00 美元（上調自 443.00 美元）。最後，Evercore ISI 在 7 月 8 日星期二的研究報告中將史賽克的目標價從 390.00 美元上調至 415.00 美元，並給予該公司 “跑贏大盤” 評級。十五位研究分析師對該股票給予了 “買入” 評級，四位給予了 “持有” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 430.10 美元。</p>
</div><p><strong>Read Our Latest Stock Report on SYK</strong></p>
<div class="lb-trans"><p><strong>閲讀我們最新的 SYK 股票報告</strong></p>
</div><h2>Stryker Profile</h2>
<div class="lb-trans"><h2>史賽克公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.</p>
<div class="lb-trans"><p>史賽克公司是一家醫療科技公司。該公司通過兩個部門運營，分別是醫療外科和神經技術，以及骨科和脊柱。骨科和脊柱部門提供用於全關節置換的植入物，如髖關節、膝關節和肩關節，以及創傷和四肢手術。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Stryker</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Back-to-School Shopping Hits $40B: 3 Retail Stocks to Watch Now</li>
<li>What is an Earnings Surprise?</li>
<li>Alphabet Stock Surges After Dodging Harsh Antitrust Remedies</li>
<li>How to Calculate Options Profits</li>
<li>Why Qualcomm Is Outperforming NVIDIA After Months of Lagging</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比史賽克更好</li>
<li>今日最大股票虧損者 - 今日最大百分比下跌者</li>
<li>開學購物達到 400 億美元：現在值得關注的三隻零售股票</li>
<li>什麼是盈利驚喜？</li>
<li>谷歌母公司股票在躲避嚴厲的反壟斷措施後大幅上漲</li>
<li>如何計算期權利潤</li>
<li>為什麼高通在經歷幾個月的滯後後表現優於英偉達</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding SYK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 SYK 持有的對沖基金嗎？</strong> 請訪問 HoldingsChannel.com 獲取史賽克公司（NYSE:SYK - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVNZSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=SYK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Stryker Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在史賽克嗎？</h2>
</div><p>Before you consider Stryker, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮史賽克之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而史賽克並不在名單上。</p>
</div><p>While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然史賽克目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Adage Capital Partners GP L.L.C.出售了 10,044 股史賽克公司股票$SYK